Literature DB >> 35946768

Efficacy of fetal left ventricular modified myocardial performance index in predicting adverse perinatal outcomes in intrahepatic cholestasis of pregnancy.

Koray Gök1, Taha Takmaz2, Osman Köse3, Bilge Kapudere1, Nevin Tüten4, Mehmet Sühha Bostancı1, Selçuk Özden1.   

Abstract

OBJECTIVE: This study aimed to evaluate the effectiveness of fetal left ventricular modified myocardial performance index in predicting adverse perinatal outcomes for intrahepatic cholestasis of pregnancy.
METHODS: A cross-sectional study was conducted, including 51 women with intrahepatic cholestasis of pregnancy and 80 healthy controls. Using Doppler ultrasonography, E-wave, A-wave, isovolumetric contraction time, isovolumetric relaxation time, and ejection time were recorded and the left ventricular modified myocardial performance index was measured.
RESULTS: Findings showed that the mean left ventricular modified myocardial performance index, isovolumetric contraction time, and isovolumetric relaxation time values were statistically significantly higher while the ejection time and E/A ratios were statistically significantly lower in the intrahepatic cholestasis of pregnancy group than the control group. In the intrahepatic cholestasis of pregnancy group, a statistically significant positive correlation was found between left ventricular modified myocardial performance index and adverse perinatal outcomes in the intrahepatic cholestasis of pregnancy group (r=0.478, p<0.001), while a statistically significant negative correlation was found between the E/A ratio and adverse perinatal outcomes (r=-0.701, p<0.001).
CONCLUSIONS: For intrahepatic cholestasis of pregnancy cases, high fetal left ventricular modified myocardial performance index values were an indicator of ventricular dysfunction, and this correlated with negative perinatal outcomes.

Entities:  

Mesh:

Year:  2022        PMID: 35946768      PMCID: PMC9574961          DOI: 10.1590/1806-9282.20220008

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.712


  18 in total

Review 1.  Evaluation of conventional Doppler fetal cardiac function parameters: E/A ratios, outflow tracts, and myocardial performance index.

Authors:  Edgar Hernandez-Andrade; Jesus Andres Benavides-Serralde; Rogelio Cruz-Martinez; Alec Welsh; Javier Mancilla-Ramirez
Journal:  Fetal Diagn Ther       Date:  2012-06-01       Impact factor: 2.587

2.  A placental phenotype for intrahepatic cholestasis of pregnancy.

Authors:  V L Geenes; Y-H Lim; N Bowman; H Tailor; P H Dixon; J Chambers; L Brown; J Wyatt-Ashmead; K Bhakoo; C Williamson
Journal:  Placenta       Date:  2011-10-20       Impact factor: 3.481

Review 3.  The (Pulsed-Wave) Doppler Fetal Myocardial Performance Index: Technical Challenges, Clinical Applications and Future Research.

Authors:  Aditi Mahajan; Amanda Henry; Neama Meriki; Edgar Hernandez-Andrade; Fatima Crispi; Linda Wu; Alec W Welsh
Journal:  Fetal Diagn Ther       Date:  2015-04-28       Impact factor: 2.587

4.  Assessment of fetal left ventricular modified myocardial performance index and its prognostic significance for adverse perinatal outcome in intrahepatic cholestasis of pregnancy.

Authors:  Aysegul Ozel; Ebru Alici Davutoglu; Mucize Eric Ozdemir; Funda Oztunc; Riza Madazli
Journal:  J Matern Fetal Neonatal Med       Date:  2018-12-20

5.  Outcome after implementation of a modern management strategy for intrahepatic cholestasis of pregnancy.

Authors:  Katherine S Kohari; Rachel Carroll; Stephanie Capogna; Andrew Ditchik; Nathan S Fox; Lauren A Ferrara
Journal:  J Matern Fetal Neonatal Med       Date:  2016-08-08

6.  Comparison of the arrhythmogenic effects of tauro- and glycoconjugates of cholic acid in an in vitro study of rat cardiomyocytes.

Authors:  J Gorelik; A Shevchuk; M de Swiet; M Lab; Y Korchev; C Williamson
Journal:  BJOG       Date:  2004-08       Impact factor: 6.531

7.  Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy.

Authors:  Cristina Manzotti; Giovanni Casazza; Tea Stimac; Dimitrinka Nikolova; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-07-05

8.  Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.

Authors:  Caroline Ovadia; Paul T Seed; Alexandros Sklavounos; Victoria Geenes; Chiara Di Ilio; Jenny Chambers; Katherine Kohari; Yannick Bacq; Nuray Bozkurt; Romana Brun-Furrer; Laura Bull; Maria C Estiú; Monika Grymowicz; Berrin Gunaydin; William M Hague; Christian Haslinger; Yayi Hu; Tetsuya Kawakita; Ayse G Kebapcilar; Levent Kebapcilar; Jūratė Kondrackienė; Maria P H Koster; Aneta Kowalska-Kańka; Limas Kupčinskas; Richard H Lee; Anna Locatelli; Rocio I R Macias; Hanns-Ulrich Marschall; Martijn A Oudijk; Yael Raz; Eli Rimon; Dan Shan; Yong Shao; Rachel Tribe; Valeria Tripodi; Cigdem Yayla Abide; Ilter Yenidede; Jim G Thornton; Lucy C Chappell; Catherine Williamson
Journal:  Lancet       Date:  2019-02-14       Impact factor: 202.731

Review 9.  Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management.

Authors:  Amber M Wood; Elizabeth G Livingston; Brenna L Hughes; Jeffrey A Kuller
Journal:  Obstet Gynecol Surv       Date:  2018-02       Impact factor: 2.347

10.  Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES).

Authors:  Lucy C Chappell; Jenny Chambers; Peter H Dixon; Jon Dorling; Rachael Hunter; Jennifer L Bell; Ursula Bowler; Pollyanna Hardy; Edmund Juszczak; Louise Linsell; Catherine Rounding; Anne Smith; Catherine Williamson; Jim G Thornton
Journal:  Trials       Date:  2018-11-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.